Bafna Pharmaceuticals (BAFNAPH) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
29 May, 2026Executive summary
Audited financial results for the quarter and year ended 31st March 2026 show year-over-year growth in revenue and profitability.
The audit report confirms a true and fair view of the financials with an unmodified opinion.
Financial highlights
Revenue from operations for FY26 was ₹15,537.37 lakhs, up from ₹15,061.74 lakhs in FY25.
Net profit for FY26 stood at ₹1,109.98 lakhs, compared to ₹415.25 lakhs in FY25.
Basic and diluted EPS for FY26 was ₹4.69, up from ₹1.76 in FY25.
Total comprehensive income for FY26 was ₹1,134.31 lakhs.
Outlook and guidance
Management remains confident regarding ongoing GST disputes and does not anticipate adverse financial outcomes.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bafna Pharmaceuticals
- Quarterly revenue and profit increased year-over-year, with key tax and GST risks under appeal.BAFNAPH
Q3 202611 Feb 2026 - Q2 FY25 saw higher revenue and profit, but compliance and receivable risks persist.BAFNAPHQ2 24/2520 Nov 2025
- Q1 FY25 posted a net loss and lower revenue, with compliance and receivable risks highlighted.BAFNAPHQ1 24/2520 Nov 2025
- Q2 FY26 profit increased to ₹312.49 lakhs, with revenue at ₹3,546.82 lakhs and higher EPS.BAFNAPHQ2 25/2611 Nov 2025
- Returned to profitability with higher revenue and completed key asset sale in the quarter.BAFNAPHQ1 25/2612 Aug 2025
- Q3 FY25 marked a return to profitability with higher revenue and no outstanding debt.BAFNAPHQ3 20256 Jun 2025
- Net profit fell despite higher revenue, with key assets held for sale and compliance milestones met.BAFNAPHQ4 24/256 Jun 2025